Skip to content

Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers

Feasibility of Remote Wound Care: Implementing a Patient-Centered Remote Wound Monitoring Solution Using a Smartphone Application

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05579743
Enrollment
148
Registered
2022-10-14
Start date
2022-07-01
Completion date
2024-06-30
Last updated
2026-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Complications, Diabetic Foot, Diabetic Foot Ulcer, Wound; Foot, Wound Heal, Wound Leg

Brief summary

The feasibility phase of the study was conducted to assess the feasibility of a novel, patient-centered, remote wound management system. The investigators will enroll 25 patients with an active diabetic foot ulcer (DFU) who present to the multidisciplinary diabetic foot clinic in Baltimore, Maryland. The RCT is being done to compare two different methods of wound monitoring for chronic wounds: remote wound monitoring using a smartphone app and in-person wound monitoring in a clinic setting. This will be a pilot non-blinded randomized controlled feasibility trial. The investigators will enroll 120 patients with an active diabetic foot ulcer (DFU) who present to the multidisciplinary diabetic foot clinic in Baltimore, Maryland. Patients will be computer randomized 1:1 to receive wound care monitoring using remote DFU monitoring technology or standard in-person monitoring for 12 weeks.

Detailed description

The purpose of this research is to determine if a smartphone mobile application, also referred to as a mobile app or simply an app, designed to capture wound measurements and analyze wound tissue distribution in real-time, can be a practical patient-centered solution for regular wound management and assessment. The app will be compared to traditional in-person wound monitoring. One of the major limitations of most literature describing remote monitoring technologies is the lack of a control group. By randomizing half of the enrolled patients in the RCT to remote monitoring via standard of care, the investigators will be able to compare patient and provider satisfaction with remote vs. in-person monitoring, as well as the wound healing outcomes.

Interventions

OTHERRemote wound monitoring technology

Healthy.io developed a professional-user wound management system that captures wound measurements and analyzes tissue distribution in real time through a smartphone application. Clinical oversight of the healing status of the wound via remote imaging and expert review allows for real time intervention when stagnation or worsening of a wound is detected. Patients with wounds on their legs will receive access to Healthy.io's mobile app and will be able to perform self-scans of their wound which will be automatically sent to the medical professionals, thus allowing them to assess the wound remotely.

Sponsors

Johns Hopkins University
Lead SponsorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Feasibility Phase: Patients were instructed on how to use the digital management system and were asked to perform one at-home wound scan per week for a total of 8 weeks. RCT: Patients will be computer randomized 1:1 to receive wound care monitoring using remote diabetic foot ulcer (DFU) monitoring technology or standard in-person monitoring for 12 weeks

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female, aged ≥ 18 years old * In treatment for lower extremity wound related to diabetic foot ulcer * Able and willing to use a smartphone to assess the wound for the duration of the study * English language proficiency

Exclusion criteria

* Patients with less than 1 dressing change per week * Patients with wound size that cannot be covered with a single app scan (out of boundary conditions include wounds that wrap around patient's entire leg) * Patients with wounds in an inaccessible location who live without a caregiver to assist in taking wound scans

Design outcomes

Primary

MeasureTime frameDescription
Part A Feasibility - Number of Participants With Wound Scan Completion8 weeksParticipants were instructed on how to use the digital management system and were asked to perform one at-home wound scan per week for a total of 8 weeks.
Participants Who Successfully Complete Weekly Wound Scan12 weeksSuccessful weekly scan rate out of 12 weeks defined as total number of participants who successfully complete a weekly wound scan

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORCaitlin Hicks, MD

Johns Hopkins School of Medicine

Participant flow

Recruitment details

Patients with an active diabetic foot ulcer (DFU) were recruited at the Johns Hopkins Hospital multidisciplinary diabetic limb preservation clinic.

Pre-assignment details

Caregivers were not enrolled in the study, however were trained alongside the enrolled participants on how to use the app for scanning.

Baseline characteristics

Characteristic
Age, Continuous65.5 years
STANDARD_DEVIATION 13.6
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
25 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
4 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
2 Participants
Race (NIH/OMB)
Black or African American
55 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants
Race (NIH/OMB)
White
12 Participants
Sex: Female, Male
Female
14 Participants
Sex: Female, Male
Male
15 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 251 / 621 / 61
other
Total, other adverse events
0 / 2532 / 6222 / 61
serious
Total, serious adverse events
0 / 2520 / 6215 / 61

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 3, 2026